Not Sure About VW EGR Valve Health Look For These Symptoms
Inotropes and their choice
1. Inotropes and their choice
Moderator: Speaker:
Dr. R. K. Verma Dr. Dharmraj Singh
2. Inotropes
Drugs that affect the strength of contraction of heart
muscle (myocardial contractility).
Positively inotropic agents ↑strength of muscular
contraction.
Negatively inotropic agents weaken the force of
muscular contractions.
Term “inotrope” generally used to describe positive
effect
3. Contd…
Both positive and negative inotropes are used in the
management of various cardiovascular conditions.
The choice of agent depends largely on specific
pharmacological effects of individual agents with
respect to the condition.
One of the most important factor affecting inotropic
state is the level of calcium in the cytoplasm of the
muscle cell.
Positive inotropes usually increase this level, while
negative inotropes decrease it.
4. Positive inotropic agents:
↑Myocardial contractility
Used to support cardiac function in conditions such as:
a) Decompensated CHF,
b) Cardiogenic shock,
c) Septic shock,
d) Myocardial infarction,
e) Cardiomyopathy, etc.
7. Negative inotropic agents
↓Myocardial contractility, and are used to ↓cardiac
workload in conditions such as angina.
While negative inotropism may precipitate or
exacerbate heart failure,
Certain beta blockers (e.g. carvedilol, bisoprolol and
metoprolol) have been believed to reduce morbidity
and mortality in congestive heart failure.
8. Contd…
1) Beta blockers
2) Calcium channel blockers:
Diltiazem
Verapamil
Clevidipine
3) Class IA antiarrhythmics such as:
Quinidine
Procainamide
Disopyramide
4) Class IC antiarrhythmics such as:
Flecainide
14. Effects of Agents
Pressors: ↑SVR & ↑BP
Inotropes: affect myocardial contractility and
enhance stroke volume
Chronotropic agents: affect heart rate
Lusotropic agents: improve relaxation during diastole
and ↓EDP in the ventricles
Dromotropic agents: Affects conduction speed
through AV node; ↑HR
Bathmotropic agents: affect degree of excitability
15. calcium
When injected IV, produce intense positive inotropic
effect lasting 10-20 minutes & manifesting as ↑SV &
LVEDP, ↓HR & SVR
Inotropic effects of Ca are enhanced in presence of
preexisting hypocalcaemia
Risk of cardiac dysrhythmias when Ca is administered
IV to patients receiving digitalis should be
considered, especially if hypokalemia is also present.
Dose: CaCl₂, 5-10 mg/kg to adults, may administered to
improve myocardial contractility & SV at the
conclusion of CPB
16. Contd…
Myocardial contractility at conclusion of CPB may be
↓by hypocalcemia because of
a) Use of K+ containing cardioplegia solutions
b) Administration of citrated stored whole blood
c) T/t of metabolic acidosis with NaHCO₃
10% solution of CaCl₂ contains more Ca than Ca
gluconate solution
17. calcium sensitizers
Pimobendan sulmazole, levosimendan are positive
inotropic drugs that improve myocardial contractility
independent of ↑in intracellular cAMP or Ca
concentration
As a results, interaction b/w actin & myosin filaments is
prolonged, & ↑myocardial contractility occurs.
18. Contd…
Desensitization of myofilaments to activating effects
of Ca may occur during myocardial ischemia &
stunning & these drugs may be particularly useful in
these circumstances.
The PDE III inhibiting properties of myofilament Ca
sensitizers produces arterial & venous dilation that
likely also contribute to the positive inotropic effects
of these drugs.
19. Levosimendan
Pyridazone-dinitrile derivative Calcium channel
sensitizer
Mode of action:
↑the sensitivity of the heart to Ca, thus ↑cardiac
contractility without a rise in intracellular Ca.
Positive inotropic effect by ↑Ca sensitivity of
myocytes by binding to cardiac troponin C in a Ca-dependent
manner.
Vasodilatory effect, by opening ATP-sensitive K
channels in vascular smooth muscle to cause smooth
muscle relaxation.
20. Contd…
Combined inotropic and vasodilatory actions result in
an ↑force of contraction, ↓preload & afterload.
By opening mitochondrial (ATP)-sensitive K-channels
in cardiomyocytes, the drug exerts a cardioprotective
effect.
↑Myocardial contractility without ↑myocardial O₂
demand, and as a consequence appears to be free of
serious arrhythmogenic effects in patients with
cardiac failure.
21. Mechanism of action of levosimendan on cardiovascular functions
Bollen Pinto et al., Current Opinion in Anesthesiology 2008, 21:168–177
22. Contd…
Loading dose: 6 to 12 μg/kg iv over 10 min F/B
Continuous infusion: 0.05-0.2 μg/kg /min for 24 hours
Hemodynamic responses are generally observed
within 5 minutes of commencement of infusion of
the loading dose.
Peak effects are observed within 10 to 30 minutes of
infusion; the duration of action is about 75-78 hours
to 1 week.
No dosage adjustments required with mild to
moderate renal failure.
Loading doses do not require adjustment with mild
to moderate hepatic impairment
23. Contd…
Indicated for inotropic support in acutely
decompensated severe CHF, refractory cardiac
failure, refractory pulmonary hypertension and
dilated cardiomyopathy..
Contraindicated in patients with:
a. Moderate-to-severe renal impairment,
b. Severe hepatic impairment,
c. Severe ventricular filling or outflow obstruction,
d. Severe hypotension and tachycardia,
e. History of torsades de pointes.
24. Contd…
Adverse effects: Common adverse drug reactions (≥1%
of patients) include:
Headache,
Hypotension,
Arrhythmias (AF, extrasystoles, atrial tachycardia, VT),
Myocardial ischaemia,
Hypokalaemia,
Nausea.
25. Contd…
CLINICAL BENEFITS:
Enhances cardiac contractility without ↑myocardial
oxygen demand, and causes vasodilation
Significantly reduces the incidence of worsening CHF
or death in patients with decompensated CHF
No evidence of arrhythmogenesis to date
POTENTIAL LIMITATIONS :
Vasodilatory properties can cause adverse effects
(headache, hypotension)
Must be administered intravenously
Limited clinical experience at present
26. Catecholamines
Dopamine, epinephrine and norepinephrine are
endogenous
Dobutamine and isoproterenol are synthetic
Sustained use or antecedent CHF can lead to down-regulation
of β-receptors and decrease efficacy
28. Dopamine(DA)
Endogenous nonselective direct and indirect
adrenergic and dopaminergic agonist
Clinical effects vary markedly with the dose.
1) Low dose: 0.5-3μg/kg/min
Activates dopaminergic receptors(specifically DA₁)
Vasodilation of renal vasculature and promotes
diuresis and natriuresis
Use of this “renal dose” does not impart any
beneficial effect on renal function.
29. Contd…
2) Moderate dose: 3-10 μg/kg/min
β₁ - stimulation ↑ myocardial contractility, HR, SBP,
and CO
Myocardial O₂ demand typiaclly↑ more than supply
3) High dose: 10-20 μg/kg/min
α₁ - effects became prominent
↑PVR & ↓renal blood flow(RBF)
Indirect effects of DA are due to release of
norepinephrine from postsynaptic sympathetic
nerve ganglion.
30. Dose Dependent effect of Dopamine
<3 mcg 3 - 10 mcg > 10 mcg
↑Contractility
Minimal change in
HR and SVR
↑ Renal BF
↑ Splanchnic BF
Modest ↑ CO
↑ Renal BF
↓Proximal Tub. Na
Absorbtion
↑ Splanchnic BF
↑ HR,
Vasoconstriction
↑/ ↓ Renal BF
↓/↑ Splanchnic BF
31. Contd…
Uses:
T/t of shock to improve CO, BP, & maintain renal
function
Often used in combination with a vaodilator (eg.
Nitroglycerin or nitroprusside), which reduce
afterload & further improve CO
Chronotropic & proarrhythmic effects of DA limit its
usefulness in some patients.
32. Contd…
Dosing & Packing:
Continuous infusion 1-20 μg/kg/min
Most commonly supplied in 5 ml (40mg/ml) ampules
containing 200 mg of DA
33. Dobutamine
Racemic mixture of two isomers with affinity for both
β₁ & β₂ receptors, with relatively higher selectivity for
β₁ receptors
Primary cardiovascular effect - ↑CO as a result of
↑myocardial contractility
↓ PVR caused due to β₂- activation usually prevents
much of ↑arterial BP
↓LV filling pressure, whereas ↑coronary blood
flow(CBF)
34. Contd…
Favorable effects on myocardial O₂ balance are
believed to make dobutamine a choice for patients
with the combination of CHF & CAD, particularly if
PVR is elevated.
It has been shown to ↑myocardial O₂ consumption,
such as during stress testing (rationale for its use in
perfusion imaging), some concern remain regarding
its use in patients with myocardial ischaemia.
Its should not be routinely used without specific
indications to facilitate separation from CPB
35. Contd…
Used in low CO states and CHF e.g. myocarditis,
cardiomyopathy, MI
If BP adequate, can be combined with afterload
reducer (Nitroprusside or ACE inhibitor)
In combination with Epinephrine/Norepinephrine in
profound shock states to improve CO and provide
some peripheral vasodilatation
Dosing & Packing:
Infusion @ 2-20 μg/kg/min
Supplied in 5-ml (50 mg/ml) ampules containing 250
mg
36. Dopexamine
Structural analogue of DA
Potentail advantage over DA because it has less β₁-
adrenergic(arrhythmogenic) & α- adrenergic effects
Because of ↓β-adrenergic effects & its specific
effects on renal perfusion, it may advantage over
dobutamine
Clinically avialable in many country since 1990, but it
has not gained widespread acceptance in practice
37. Contd…
Dosing & Packing:
Infusion should be started @0.5μg/kg/min, ↑ to
1μg/kg/min at interval of 10-15 min to maximum
infusion rate 6μg/kg/min.
38. Epinephrine(adrenaline)
Endogenous catecholamine synthesized in the
adrenal medulla
Direct stimulation of β₁- receptors of the myocardium
cause ↑BP, CO & myocardial O₂ demand by
↑contractility & HR
α₁- stimultion ↓splanchnic & RBF but ↑coronary
perfusion pressure(CPP) by ↑aortic DP
SBP rises, although β₂- mediated vasodilation in
skeletal muscle may ↓DP
β₂- stimulation also relaxes bronchial smooth muscle
41. Contd…
Dosing & Packing:
Emergency situation (eg, cardiac arrest & shock), iv
bolus 0.05-1 mg, depending on the severity of
cardiovascular compromise
Major anaphylactic reactions 100-500μg (repeated, if
necessary) followed by infusion
To improve myocardial contractility or HR, a
continuous infusion is prepared (1 mg in 250 ml
[4μg/ml]) & run @ 2-20μg/min
42. Contd…
Reduce bleeding from operative sites
Local anesthetics solutions containing 1:200,000
(5μg/ml) or 1:400,000 (2.5μg/ml)- less systemic
absorption & longer duration of action
Epinephrine is available in vials & prefilled syringes
containing:
a) 1:1000 (1mg/ml)
b) 1:10,000 (0.1mg/ml [100μg/ml])
c) 1:100,000 (10μg/ml)- for pediatric use
43. Contd…
Common contraindication:
Hypertension.
Pheochromocytoma.
Caution with heart failure angina and
hyperthyroidism.
44. Isoprenaline (Isoproterenol)
Synthetic catecholamine
Non-specific pure β- agonist with minimal alpha-adrenergic
effects.
β₁- effects ↑HR, contractility , CO
SBP may ↑ or remain unchanged, but β₂- stimulation
↓PVR & DBP
↑Myocardial O₂ demand while ↓O₂ supply, making
isoproterenol or any pure β- agonist a poor inotropic
choice in most situations
45. Contd…
Causes inotropy, chronotropy, and systemic and
pulmonary vasodilatation.
Indications: bradycardia, decreased CO,
bronchospasm (bronchodilator).
46. Contd…
Dosing & Packing:
Occasionally used to maintain HR following heart
transplantation.
Dose starts at 0.01 mcg/kg/min and is increased to
2.0 mcg/kg/min for desired effect.
Avoid in patients with subaortic stenosis, and
hypertrophic cardiomyopathy or TOF lesions because
increases the outflow gradient
Supplied in 1-ml (2 mg/ml) ampules containing 2 mg
47. Norepinephrine (Noradrenaline)
Direct α₁- stimulation with little β₂- activity induces
intense vasoconstriction of arterial & venous vessels
↑Myocardial contractility from β₁- effects, along with
peripheral vasoconstriction contributes to ↑arterial
BP
↑SBP & DBP both, but ↑afterload & reflex
bradycardia prevent any ↑CO
↓Renal & splanchnic blood flow & ↑myocardial O₂
requirements limit the outcome benefits of
norepinephrine in management of refractory shock.
48. Contd…
Norepinephrine has been used with an α- blocker (eg,
phentolamine) in an attempt to take advantage of its
β- activity without the profound vasoconstriction
caused by α- stimulation
Extravasation of norepinephrine at the site of IV
administration can cause tissue necrosis
Dosing & Packing:
Bolus 0.1μg/kg or
Continuous infusion @ 2-20μg/kg/min (due to its
short half life)
Ampules contain 2 mg of norepinephrine in 4 ml
49. prostaglandins
The effects of prostaglandins on cardiac function are
complex & depend on direct inotropic effects, the
activity of the SNS relative to PNS, & the metabolic
status of heart
PGE₂ produces an ↑in HR & myocardial contractility
by direct inotropic effects as well as by ↑reflex SNS
activity
PGE₂(Dinoprostone) produces ↑ in HR &CO
50. CADIAC GLYCOSIDES
Purified cardiac glycoside (clinically useful; Digoxin,
digitoxin, & ouabain) extracted from the foxglove plant,
Digitalis lanata.
Widely used in the treatment of various heart conditions,
namely AF, atrial flutter and sometimes heart failure that
cannot be controlled by other medication.
Mechanism of Action:
Positive inotropic effect include direct on heart that modify
its electrical & mechanical activity & indirect effects
evoked by reflex alteration in ANS
51. CONTD…
Selectively & reversibly inhibit Na-K ATP ion transport
system (Na pump) located in the sarcolemma of cardiac
cell membranes→
↑Na+ concentration in the cardiac cells leads to
↓extrusion of Ca2+ by Na+ pump mechanism
↑intracellular concentration of Ca2+ is responsible for
positive inotropic effect of cardiac glycosides
Positive inotropic effects produced by cardiac glycosides
occur without change in HR & associated with ↓LV
preload, afterload, wall tension, & O₂ consumption in the
failing heart.
52. Contd…
• ↑PNS activity due to sensitization of arterial
baroreceptors (carotid sinus) & activation of vagal
nuclei & nodose ganglion in the CNS
• ↓activity of SA node & prolongs the effective
refractory period, & thus the time for conduction of
cardiac cardiac impuse through AV node
• Slowed HR especially in presence of AF
53. Digoxin Digitoxin
Avg digitalization dose
Oral 0.75-1.50 mg 0.8-1.2 mg
Intravenous 0.5-1.0 mg 0.8-1.2 mg
Avg daily maintenance dose
Oral 0.125-0.500 mg 0.05-0.20 mg
Intravenous 0.25 mg 0.1 mg
Onset of effect
Oral 1.5-6.0 hrs 3-6 hrs
Intravenous 50-30 mins 30-120 mins
Absorption from the GIT 75% 90-100%
Plasma protein binding 25% 95%
Route of elimination Renal Hepatic
Enterohepatic circulation Minimal Marked
Elimination half-time 31-33 hrs 5-7 days
Therapeutic plasma
0.5-2.0 ng/ml 10-35 ng/ml
concentration
54. Ouabain
Dose:
1.5-3.0 mcg/kg iv to provide rapid increases in
myocardial contractility or to decrease the heart
ratein rapid ventricular response AF
55. Selective Phosphodiesterase
inhibitors
(noncatecholamine, nonglycoside cardiac inotropic agents)
Selective PDE exert competitive inhibitory action on
an isoenzyme fraction of PDE (PDE III)
↓hydrolysis of cAMP & cGMP
↑intracellular concnof cAMP & cGMP in myocardium &
vascular smooth muscle
Stimulation of protein kinases C
Phosphorylate substance & inward movement of Ca2+
56. Contd…
Positive inotropic effect with vascular & airway
smooth muscle relaxation
Positive inotropic effect due to inhibition of cardiac
PDE III, leading to ↑myocardial cAMP
Selective PDE inhibitors act independently of β-
adrenergic receptors & ↑myocardial contractility in
patients with myocardial depression from β-receptor
blockade & those who have become refractory to
catecholamine therapy
57. Contd…
Selective PDE III inhibitors exceeds cardiac glycosides
& is complementary & synergistic to the action of
catecholamines.
These drugs can be used in conjuction with digitalis
without provoking digitalis toxicity
Mx of Ac cardiac failure (as after MI) in Pts who
would benefit from combined inotropic & vasodilator
therapy
Amrinone, Milrinone, Enoximone, Piroximone
58. Amrinone
Bipyridines derivative, selective PDE III inhibitor &
produces dose dependent positive inotropic &
vasodilator effects
Non-receptor mediated activity based on selective
inhibition of Phosphodiesterase Type III enzyme resulting
in cAMP accumulation in myocardium
cAMP increases force of contraction and rate and extent
of relaxation of myocardium
Inotropic, vasodilator and lusotropic effect
↑CO & ↓LVEDP,
HR & SBP may↑
59. CONTD…
Advantage over catecholamines:
Independent action from β-receptor activation,
particularly when these receptors are downregulated
(CHF and chronic catecholamine use)
Oral/ IV
Initial injection single dose: 0.5-1.5 mg/kg IV, ↑CO with
in 5 min, with detectable positive inotropic effect
persisting for approx 2 hrs
Continuous infusion: after initial injection 2-10
μg/kg/min
Recommended maximum daily dose 10 μg/kg including
the initial dose
60. Contd…
Patients who have failed to respond to
catecholamine may respond to amrinone
Vasodilating effects of amrinone can accelerate the
cooling rate of core temperature during deliberate
mild hypothermia for neurosurgical procedure.
Side effects:
Occasional hypotension
Thrombocytopenia
61. Milrinone
Like amrinone positive inotropic & vasodilator effects
Minimal effects on HR & myocardial O₂ consumption
↑CO by improving contractility, ↓SVR, PVR, lusotropic
effect; ↓preload due to vasodilatation
Unique in beneficial effects on RV function
Protein binding: 70%
Half-life is 1-4 hours
Elimination: primarily renally excreted
Load with 50 μg/kg over 30 mins followed by 0.25 to 0.75
μg/kg/min
62. Milrinone
Minimal ↑ HR
↑ CO
Minimal ↑ in
O2 demand ↓ SVR
↓ PVR
Diastolic
Relaxation
63. Enoximone & piroximone
Imidazole derivatives that act as highly selective PDE III
inhibition to ↑myocardial contractility
Half-life 4.3 hrs
Metabolized mainly by liver
Dose: 0.5 mg/kg IV f/b 5-20 μg/kg/min continuous
infusion
64. COMPARISON BETWEEN LEVOSIMENDAN,
MILRINONE AND DOBUTAMINE
Feature Levosimendan Milrinone Dobutamine
Class Calcium channel
sensitizer
Phosphodiesterase-III
inhibitor
Catecholamine(β-
adrenergic agent)
↑intracellular Ca
concentrations
No Yes Yes
Vasodilator Coronary and
systemic
Peripheral Mild peripheral
↑Myocardial O₂
demand
No No Yes
Arrhythmogenic
potential
Rare and may be due
to QTc prolongation
Ventricular and
supraventricular
arrhythmias
Ventricular ectopic
activity; less
arrhythmogenic than
milrinone
Adverse events Headache,
hypotension
Ventricular
irregularities,
hypotension, headache
Tachycardia and
increased SBP on
overdosage
65. glucagon
Polypeptide hormone produced by α- cell of
pancreas
Enhances formation of cAMP
Evoke the release of catecholamine
Principal cardiac indication: to ↑myocardial
contractility & HR in the presence of β-adrenergic
blockade.
Because glucagon is peptide, it must be administered
IV or IM
66. Contd…
Cardiovascular effects:
Rapid injection (1-5 mg IV to adults) or a continuous
infusion (20 mg/hr), reliabily ↑SV & HR independent
of adrenergic stimulation
Tachycardia may sufficienlty with augmented CO
Abrupt ↑in HR can occur when administered to
patients in atrial fibrillation
MAP may ↑modestly, whereas SVR is unchanged or
↓
Enhance automaticity in the SA & AV nodes without
↑automaicity of ventricles
67. Contd…
Renal effect: similar to dopamine, but less potent
Chronic administration is not effective in evoking
sustained positive inotropic & chronotropic effects.
Side effects:
Nausea & vominting
Hyperglycemia & paradoxical hypoglycemia
Hypokalemia
Systemic hypertension in patients unrecognized
pheochromocytoma
68. Beta blockers
β-Receptor blockers have variable degree of
selectivity for the β₁- receptors
More selective β₁- receptor blockers has less
influence on bronchopulmonary & vascular β₂-
receptors.
Theoretically, a selective β₁ -blockers would have less
of an inhibitory effect on β₂-receptors & therefore ,
might be preferred in patients with COPD or PVD
70. Contd…
Patients with PVD could potentially have a ↓in blood
flow if β₂-receptors, which dilate the arterioles, are
blocked.
Many of β-blockers have some agonist activity;
although they would not produce effects similar to
full agonist(such as epinephrine)
Β-blockers with ISA may not be beneficial as β-
blockers without ISA in treating patients with
cardiovascular disease.
71. Esmolol
Ultrashort-acting selective β₁-antagonist that ↓HR,
& to a lesser extent, BP
Successfully used to prevent tachycardia &
hypertension in response to perioperative stimuli,
such as intubation, surgical stimulation, &
emergence.
For example, esmolol (0.5-1 mg/kg) attenuates the
rise in BP & HR that usually accompanies ECT without
significantly affecting seizure duration.
72. Contd…
Although esmolol is considered to be cardioselective, at
higher doses it inhibits β₂-receptors in bronchial and
vascular smooth muscle.
The short DOA is due to rapid redistribution (distribution
half-life 2 min) & hydrolysis by RBC esterase (elimination
half-life 9 min)
S/E can be reversed with in minutes by discontinuing its
infusion
As with all β₁-antagonist, esmolol should be avoided in
patients with sinus bradycardia, heart block >1⁰,
cardiogenic shock, overt heart failure.
73. Contd…
Dosing & Packing:
Short term therapy: Bolus (0.2-0.5 mg/kg), such as
attenuating the cardiovascular response to
laryngoscopy & intubation.
Long-term treatment: typically initiated with a
loading dose of 0.5mg/kg administered over 1 min
f/b a continuous infusion of 50μg/kg/min to
maintain therapeutic effect.
74. Contd…
If this fail to produce sufficient response within 5 min,
the loading dose may be repeated and the infusion
↑by increments of 50μg/kg/min every 5 min to a
maximum 200μg/kg/min.
Multidose vials for bolus administration containing 10
ml of drug (10mg/ml)
Ampules for continuous infusion (2.5g in 10ml) also
available but must be diluted prior to administration to
a concentration of 10mg/ml.
75. Choice of inotrope
Guided :
The expected need for inotropes
clinical evidence of depressed myocardial function
Empirical drug choice and titration, with careful
hemodynamic monitoring
76. Predictive factors of inotropic support, as
highlighted by several studies.
Low ejection fraction (< 45%)
History of congestive heart failure
Cardiomegaly
High LVEDP following ventriculogram
MI within 30 days of operation*
Older age (> 70 years)
Longer duration of aortic cross-clamping
Prolonged cardiopulmonary bypass*
Urgent operation
Re-operation*
Female gender*
Diabetes mellitus
LVEDP = left ventricular end-diastolic pressure; MI = myocardial infarction.
* statistical significance for coronary artery bypass surgery only.
77. Ideal positive inotrope
Enhance contractility without any significant increase
in heart rate preload, afterload, and myocardial
oxygen consumption.
Enhance the diastolic function
Maintain the diastolic coronary perfusion pressure
and thus an adequate myocardial blood flow.
It finally should have rapid titration times and onset
of action and a short half-life
78. Contd…
Catecholamines are the mainstay of current inotropic
treatment
they can be divided into
more potent (epinephrine, isoproterenol,
noradrenaline) and
milder (dopamine, dopexamine, dobutamine
79. Indications in specific settings
Coronary artery bypass graft surgery:
In most cases, no or only mild inotrope requirement.
Inotropes may be needed in case of preexisting
ventricular dysfunction or in case of unsuccessful
revascularization if the intra-aortic balloon pump
alone is not enough.
Emergency revascularization of acute myocardial
infarction, dobutamine and PDE inhibitors.
Off-pump coronary artery bypass graft surgery
(dopamine, dobutamine)
80. Contd…
Chronic heart failure:
Combination therapy (i.e. a PDE inhibitor
administered along with a beta-adrenergic inotrope,
dobutamine or epinephrine) may therefore be the
treatment of choice in these patients
Diastolic dysfunction:
No inotropes at all (or inotropes with a better effect
on ventricular relaxation, such as PDE inhibitors, if
systolic dysfunction coexists)
81. Contd…
Valvular surgery
Moderately severe aortic stenosis- Inotropic support
is rarely needed
Chronic aortic insufficiency- Requiring adequate
preload and inotropes
Mitral stenosis, chronic mitral regurgitation-
Treatment with inotropes is warranted.
Acute aortic and mitral regurgitation- require
aggressive inotropic support even preoperatively
Tricuspid regurgitation-Inotropes are beneficial
82. Contd…
Orthotopic cardiac transplantation:
Routine inotropic support includes isoproterenol (to
increase the automaticity, inotropism and pulmonary
vasodilation) and dopamine (to add further support
whilst maintaining the systemic perfusion pressures).
Right ventricular dysfunction:
heart transplantation,
lung transplantation
pulmonary thromboendoarterectomy
left ventricular assist device implantation,
inadequate myocardial protection
83. Successful management
Right ventricular
afterload The contractile
strength
maintenance of
the aortic blood
pressure
Pulmonary
vasodilators
inotropes :
• dobutamine,
•isoproterenol,
• epinephrine,
•PDE inhibitors
Vasoconstrictors
85. Summary
Understand appropriate clinical application of
vasopressors and inotropic agents.
In hyperdynamic septic shock, norepinephrine or
phenylephrine is first-line agent. Vasopressin as
second-line agent to reduce need for other pressors.
In cardiogenic shock, norepinephrine is preferred
initial agent. After establishing adequate perfusion,
Dobutamine added.
86. Contd…
In anaphylactic shock, 1st line agent is Epinephrine
followed by Vasopressin as second line agent.
Epinephrine is the 1st line agent in hypotension
after CABG.
In both neurogenic shock and anesthesia-induced
hypotension, Phenylephrine is the 1st line agent.
In Septic Shock, 1st line agent is Norepinephrine (Levophed). Alpha-1 activation and vasoconstriction raises MAP. Pure vasoconstriction can cause reflex bradycardia and decreased CO. Beta-1 counteracts this. Furthermore, in septic shock, there is often decrease in cardiac function; Beta-1 improves CO.
Phenylephrine (Neosynephrine) can also be used as 1st line agent in hyderdynamic sepsis for pure vasoconstriction, if there is no evidence of depressed cardiac function (Ex. Tachycardia).
2nd line agents in septic shock are Vasopressin and Epinephrine. Vasopressin is an antidiuretic hormone, used in clinical settings of diabetes insipidus and esophageal variceal bleed. Vasopresin can be used as 2nd line agent in refractory septic shock. Though no significant improvement was shown in short-term mortality, pt receiving Vasopressin required less Levophed. Vasopressin may be used to decreased need for other pressors.
Dopamine is the preferred initial agent in heart failure patients. Dopamine in low dose (1-2mcg/kg/min) has predominant effect on Dopamine-1 receptor in renal, mesenteric, cebebral and coronary beds, resulting in selective vasodilation and increased renal perfusion; however, it has NOT been shown to improve renal function. At dose 5-10mcg/kg/min, stimulates Beta-1 and increases Cardiac Output.
Milrinone, which is a phosphodiesterase (PDE) inhibitor, has similar effects as Dobutamine but with lower incidence of dysrhythmias. Milrinone can be used in patients with impaired cardiac function and medically refractory heart failure. But cannot be used if pt is hypotensive.
3) In heart failure with cardiogenic shock, norepinephrine is preferred initial agent. After establishing adequate perfusion, Dobutamine can be added. Dobutamine activity on Beta-1 increases contractility and HR, thereby increasing cardiac output. Beta-2 causes vasodilation; heart has less pressure to pump against. Reduces left ventricular filling pressure.
4) In anaphylactic shock, 1st line agent is Epinephrine (Adrenalin), followed by Vasopressin as second line agent.
5) Alpha-specific activity of Neosynephrine is ideal in both neurogenic shock and anesthesia-induced hypotension.
6) Epinephrine (Adrenalin) is the 1st line agent in hypotension after CABG. High vagal output following CABG can cause decreased HR/contractility and hypotension.